Recovery Rate in Secondary Hypothyroidism

Sponsor
Nova Scotia Health Authority (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05276856
Collaborator
(none)
90
9.2

Study Details

Study Description

Brief Summary

The aim of this project is to assess the rate of recovery of secondary hypothyroidism in patients with pituitary disorders.

Condition or Disease Intervention/Treatment Phase

Detailed Description

The study will be conducted in three stages.

Stage 1 ( Patient identification and enrollment)

We will generate a list of all SHT patients from the HNP database and all patients will be contacted by the principal investigator (or their designate) regarding the study. Those patients who agree to participate in the study will be given a written consent form. We aim to enrol approximately 90 -100 patients for the study. Laboratory samples for serum TSH and T4 levels will be collected to confirm that all patients are adequately replaced for SHT. Those patients who are not adequately replaced and have low T4 will be excluded from the study.

Stage 2 (T4 withdrawal protocol)

Stepwise T4 replacement therapy will be initiated as follows.

Step 1:
  • Reduce the dose of T4 therapy by 50% and recheck serum T4 after 2 weeks.

  • If serum T4 is normal, go to step 2.

  • If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).

The rationale for testing serum T4 after 2 weeks is that the half life of T4 is up to 7 days and early testing will potentially give false results. Furthermore, serum T3 is not a reliable test in patients taking T4 therapy and will not be requested 6.

Step 2:
  • Discontinue T4 therapy altogether and recheck serum TSH and T4 after 2 weeks.

  • If serum T4 is normal, go to step 3.

  • If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).

Step 3:
  • Recheck serum TSH and T4 after 8 weeks.

  • If serum TSH and T4 levels are normal, these patients will be regarded as having successful T4 withdrawal.

  • If T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).

Stage 3 (Analysis)

Study Design

Study Type:
Observational
Anticipated Enrollment :
90 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Rate of Recovery of Secondary Hypothyroidism in Patients With Pituitary Disorders.
Anticipated Study Start Date :
Mar 10, 2022
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Dec 15, 2022

Outcome Measures

Primary Outcome Measures

  1. Percentage of patients achieving euthyroid status [12 weeks]

    Percentage of patients able to maintain normal TSH/T4 without thyroxine replacment

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Confirmed diagnosis of secondary hypothyroidism who are currently taking T4 replacement therapy
Exclusion Criteria:
  • uncontrolled cardiovascular disease

  • uncontrolled congestive heart failure

  • uncontrolled mental health disorder

  • not adequately replaced and have low T4 level.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Nova Scotia Health Authority

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Syed Ali Imran, Dr S. Ali Imran MBBS, FRCP, FRCPC Professor of Medicine Division of Endocrinology Dalhousie University, Halifax, NS Ph: 902 4732952 Fax: 902 4733726, Nova Scotia Health Authority
ClinicalTrials.gov Identifier:
NCT05276856
Other Study ID Numbers:
  • RR in secondary hypothyroidism
First Posted:
Mar 11, 2022
Last Update Posted:
Mar 11, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 11, 2022